ERBB2 and neoplasm: The 89Zr-DFO-scFv-PEG-Cy5-C dots were systemically administered to non-tumor-bearing or BT-474 tumor-bearing mice, for assessment of biodistribution, radio stability, whole-body clearance, and HER2-targeted uptake in vivo.